Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 19/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9110507 | 0.99 | TPSAB1 (0.48) | TPSAB1KCNH2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL6870792 | 0.95 | TPSAB1 (0.50) | TPSAB1KCNH2CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL9110053 | 0.95 | TPSAB1 (0.49) | TPSAB1KCNH2CYP2C9CYP2C19 | |
| SCHEMBL2043935 | 0.92 | TPSAB1 (0.51) | TPSAB1KCNH2CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL2050747 | 0.92 | TPSAB1 (0.51) | TPSAB1KCNH2CYP2C9CYP2C19 | |
| SCHEMBL1275311 | 0.91 | TPSAB1 (0.43) | TPSAB1KCNH2CYP2C9CYP2C19CYP3A4 | |
| Hydrochloric Acid SCHEMBL9110665 | 0.91 | TPSAB1 (0.43) | TPSAB1KCNH2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL6871322 | 0.89 | TPSAB1 (0.42) | TPSAB1 | |
| Fumaric Acid SCHEMBL2282789 | 0.88 | TPSAB1 (0.49) | TPSAB1KCNH2CYP2C9CYP2C19 | |
| SCHEMBL12643122 | 0.88 | TPSAB1 (0.59) | TPSAB1KCNH2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480232-B1 | DISUBSTITUTED ]4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES | SANOFI SA (FR) | 2013-10-02 | — | — | EP | claimed |
| US-20120142735-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES | SANOFI (FR) | 2012-06-07 | — | — | US | claimed |
| EP-2480232-B1 | DISUBSTITUTED ]4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES | SANOFI SA (FR) | 2013-10-02 | — | — | EP | disclosed |
| EP-2480232-B1 | DISUBSTITUTED ]4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES | SANOFI SA (FR) | 2013-10-02 | — | — | EP | disclosed |
| EP-2480232-A1 | DISUBSTITUTED ]4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES | SANOFI (FR) | 2012-08-01 | — | — | EP | disclosed |
| US-20120142735-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES | SANOFI (FR) | 2012-06-07 | — | — | US | disclosed |
| US-20120142735-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES | SANOFI (FR) | 2012-06-07 | — | — | US | disclosed |
| US-20120142735-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES | SANOFI (FR) | 2012-06-07 | — | — | US | disclosed |
| WO-2011106334-A1 | TREATMENT OF DERMATOLOGICAL ALLERGIC CONDITIONS | SANOFI (FR) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011078983-A1 | TREATMENT FOR INFLAMMATORY BOWEL DISEASE | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011022449-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011022449-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142735-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES | CMA1, TPSB2, TPSAB1 | TPSAB1 3/4885KCNH2 495/4885CYP2C9 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.